SIONNA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
SIONNA THERAPEUTICS, INC. (SION) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- SIONNA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $2.70M, a 2600.00% increase year-over-year.
- SIONNA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $11.00M.
- SIONNA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $8.70M.
- SIONNA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $5.90M.
- SIONNA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $14.70M, a 3575.00% increase from fiscal 2024.
- SIONNA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $400.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-06 | $13.70M 10-Q · filed 2026-08-06 | $22.40M derived: sum of 3 quarters · filed 2026-08-06 | $28.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $11.00M 10-Q · filed 2026-05-12 | $19.70M derived: sum of 2 quarters · filed 2026-05-12 | $25.60M derived: sum of 3 quarters · filed 2026-05-12 | $25.70M derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | $8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $14.60M derived: sum of 2 quarters · filed 2026-03-02 | $14.70M derived: sum of 3 quarters · filed 2026-03-02 | $14.70M 10-K · filed 2026-03-02 |
| 2025-09-30 | $5.90M 10-Q · filed 2025-11-05 | $6.00M derived: sum of 2 quarters · filed 2025-11-05 | $6.00M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $100.00K 10-Q · filed 2025-08-11 | $100.00K 10-Q · filed 2025-08-11 | ||
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-02 | |||
| 2024-12-31 | $400.00K 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |